Publications by authors named "C Desvignes"
Background: In recent years, human microbiome research has flourished and has drawn attention from both healthcare professionals and general consumers as the human microbiome is now recognized as having a significant influence on human health. This has led to the emergence of companies offering microbiome testing services. Some of these services are sold directly to the consumer via companies' websites or via medical laboratory websites.
View Article and Find Full Text PDFDespite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the blood-brain barrier after intravenous injection and the significant efflux of drugs, including monoclocal antibodies, after administration into the cerebrospinal fluid. We hypothesized that this efflux was linked to the presence of a FcRn receptor in the blood-brain barrier.
View Article and Find Full Text PDFArticle Synopsis
- Eculizumab is a medicine used to treat certain kidney diseases, and scientists want to find a better way to give the right amount to patients, avoiding high doses that can be costly.
- They studied blood samples from 44 patients to understand how the drug leaves the body and whether a new model can predict its levels better than a simple one.
- The results showed that how eculizumab is eliminated from the body isn’t straightforward and depends on the person’s weight, which helps doctors decide the best dose for each patient.
Aims: The exposure-response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time-dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed to investigate the exposure-response relationships of bevacizumab in metastatic colorectal cancer (mCRC) patients while mitigating potential biases.
Methods: Bevacizumab pharmacokinetics was described using target-mediated drug disposition modelling.
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
J Intern Med
December 2023
Article Synopsis
- Bevacizumab, a monoclonal antibody, is used to treat hereditary hemorrhagic telangiectasia (HHT), but this is the first randomized trial investigating its effectiveness.
- In a double-blind study involving 24 patients, those treated with bevacizumab showed a greater decrease in blood transfusions compared to the placebo group, with significant improvements in hemoglobin levels over six months.
- Despite some positive results, the trial was underpowered, meaning more research is needed to confirm that bevacizumab helps reduce the need for blood transfusions in HHT patients, especially in those exposed to higher doses.